januari 27, 2022

Ectin Research AB to evaluate further use of MFA-370 in collaboration with Sahlgrenska Academy

Ectin Research AB today announces that it has entered into a Contract Research agreement with the Sahlgrenska Academy at the University of Gothenburg. The aim is to preclinically investigate whether the company’s cancer treatment MFA-370, presently being trialled for the treatment of metastatic urothelial bladder cancer, could also potentially be used to treat another cancer indication.

Ectin has shown in preclinical studies that MFA-370 has an anti-proliferative (growth-inhibiting) effect and gives rise to specific cancer cell death, i.e. it has an anti-cancer effect. The company has previously stated that in 2022 it would aim to search for a follow-up indication for metastatic urothelial bladder cancer, where MFA-370 could be used as a treatment method. Now, in collaboration with Sahlgrenska Academy at the University of Gothenburg, Ectin intends to begin a preclinical study in a laboratory environment to investigate whether it can broaden the scope of its MFA-370 cancer therapy. Ectin’s assessment is that these preclinical tests within an additional cancer indication will not give rise to additional capital requirements.

The first preliminary data from the collaboration with Sahlgrenska Academy is expected to be available during Q2 2022.

Ectin Research’s CEO Anna Sjöblom-Hallén: “The agreement with Sahlgrenska Academy is in line with the company’s strategy and objectives for broadening its future operations. The collaboration that has now begun is a concrete and important step that will bring us closer to choosing a follow-up indication for metastatic urothelial bladder cancer, where MFA-370 could potentially be used as a cancer treatment.”